deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT04358458

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts

Sponsor: Genmab

Conditions Chronic Lymphocytic Leukemia Diffuse Large B-cell Lymphoma Follicular Lymphoma High-grade B-cell Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Primary Mediastinal Large B-cell Lymphoma Small Lymphocytic Lymphoma
Interventions Epcoritamab GEN3009
Updated 16 times since 2020 Last updated: Oct 23, 2024 Started: Mar 13, 2020 Primary completion: Nov 21, 2022 Completion: Jul 28, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on any safety or regulatory concerns.

Other terminated trials from Genmab

See all terminations from Genmab

Other Chronic Lymphocytic Leukemia trials with similar outcome

Browse all Chronic Lymphocytic Leukemia trials

A PHASE1/PHASE2 clinical study on Chronic Lymphocytic Leukemia and Diffuse Large B-cell Lymphoma, this trial is terminated or withdrawn. The trial is conducted by Genmab and has accumulated 16 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Dec 2020 · 3 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Jun 2023 · 9 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – present · 20 months · monthly snapshot

Change History

16 versions recorded

  1. Nov 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2024 — Nov 2024 [monthly]

    Terminated PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Oct 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: Recruiting → Terminated

  5. Jul 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

  2. Sep 2022 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jan 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. Sep 2021 — Jan 2022 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Sep 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  10. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

  11. May 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Mar 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genmab
Data source: Genmab

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Badalona, Spain , Barcelona, Spain , Charleston, United States , Cleveland, United States , Columbus, United States , Copenhagen, Denmark , Dallas, United States , Denver, United States , Houston, United States and 5 more locations